Remove Arcturus Remove Blogging Remove Marketing
article thumbnail

Bio Roundup: Alnylam’s Billions, COVID-19 Vaccines, Moma Debuts & More

Xconomy

The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash. Late last year Alnylam (NASDAQ: ALNY ) began exploring potential royalty deals for inclisiran, a drug that uses RNA interference to lower cholesterol.

Equity 84
article thumbnail

Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More

Xconomy

The strength of the IPO market is notable because the first quarter is typically the slowest time of the year for companies to go public, EY told Xconomy. The number of companies filing to go public in the U.S. Life science companies accounted for nearly one third of the quarter’s IPOs.